Skip to main content
SpringerLink
Log in

La chimiothérapie intrapéritonéale de consolidation

  • Chapter
Les cancers ovariens

Part of the book series: Abord clinique ((ONCOLPRAT))

  • 319 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159(18): 1704–7

    CAS  PubMed  Google Scholar 

  2. Bonte FJ, Storaasli JP, Weisberger AS (1956) Comparative evaluation of radioactive colloidal gold and nitrogen mustard in the treatment of serous effusions of neoplastic origin. Radiology 67(1): 63–6

    CAS  PubMed  Google Scholar 

  3. Dedrick RL, Myers CE, Bungay PM et al. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1): 1–11

    CAS  PubMed  Google Scholar 

  4. Los G, Mutsaers PH, Lenglet WJM et al. (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25: 389–94

    Article  CAS  PubMed  Google Scholar 

  5. Menczer J, Ben-Baruch G, Rizel S et al. (1992) Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 46: 222–5

    Article  CAS  PubMed  Google Scholar 

  6. Tarraza HM, Boyce CR, Smith WG et al. (1993) Consolidation intraperitoneal chemotherapy. Gynecol Oncol 50: 287–90

    Article  PubMed  Google Scholar 

  7. Dufour P, Bergerat JP, Barats JC et al. (1994) Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73: 1865–9

    CAS  PubMed  Google Scholar 

  8. Barakat RR, Almadrones L, Venkatraman ES et al. (1998) A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 69(1): 17–22

    Article  CAS  PubMed  Google Scholar 

  9. Barakat RR, Sabbatini P, Bhaskaran D et al. (2002) Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up. J Clin Oncol 20(3): 694–8

    Article  PubMed  Google Scholar 

  10. Topuz E, Eralp Y, Saglam S et al. (2004) Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol 92(1): 147–51

    Article  CAS  PubMed  Google Scholar 

  11. Tournigand C, Louvet C, Molitor JL et al. (2001) Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol 83(2): 198–204

    Article  CAS  PubMed  Google Scholar 

  12. Tournigand C, Louvet C, Molitor JL et al. (2002) Consolidation intraperitoneal chemotherapy in advanced ovarian cancer with pathological complete response or with microscopical residual disease. A GERCOR study. ASCO 883

    Google Scholar 

  13. Piccart MJ, Floquet A, Scarfone G et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13Suppl 2: 196–203

    PubMed  Google Scholar 

  14. Berek JS, Markman M, Blessing JA et al. (1999) Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol 74(1): 48–52

    Article  CAS  PubMed  Google Scholar 

  15. Berek JS, Markman M, Stonebraker B et al. (1999) Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol 75(1): 10–4

    Article  CAS  PubMed  Google Scholar 

  16. Nardi M, Cognetti F, Pollera CF et al. (1990) Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 8(6): 1036–41

    CAS  PubMed  Google Scholar 

  17. Willemse PH, de Vries EG, Mulder NH et al. (1990) Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 26(3): 353–8

    CAS  PubMed  Google Scholar 

  18. Pujade-Lauraine E, Guastalla JP, Colombo N et al. (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin Oncol 14(20: 343–50

    CAS  PubMed  Google Scholar 

  19. Bruzzone M, Rubagotti A, Gadducci A et al. (1997) Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol 65(3): 499–505

    Article  CAS  PubMed  Google Scholar 

  20. Stewart JA, Belinson JL, Moore AL et al. (1990) Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50(19): 6302–10

    CAS  PubMed  Google Scholar 

  21. Steis RG, Urba WJ, VanderMolen LA et al. (1990) Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8(10): 1618–29

    CAS  PubMed  Google Scholar 

  22. Freedman RS, Edwards CL, Kavanagh JJ et al. (1994) Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 16(3): 198–210

    CAS  PubMed  Google Scholar 

  23. de Gramont A, Gangji D, Louvet C et al. (2002) Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 86(1): 102–3

    PubMed  Google Scholar 

Download references

Authors
  1. C. Tournigand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Plantade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. de Gramont
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Tournigand, C., Plantade, A., de Gramont, A. (2006). La chimiothérapie intrapéritonéale de consolidation. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_23

Download citation

  • DOI: https://doi.org/10.1007/2-287-30921-7_23

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25168-9

  • Online ISBN: 978-2-287-30921-2

Publish with us

Policies and ethics

Search

Navigation